Search results for "Venous Thrombosi"

showing 10 items of 184 documents

The Essential Thrombocythemia, Thrombotic Risk Stratification, and Cardiovascular Risk Factors

2020

Essential thrombocythemia is a rare hematological malignancy with good overall survival, but moderate to high risk of developing arterial or venous thrombosis lifelong. Different thrombotic risk scores for patients with essential thrombocythemia have been proposed, but only one of them (the IPSET-t scoring system) takes into account the classical cardiovascular risk factors as one of the scoring items. Currently, in clinical practice, the presence of cardiovascular risk factors in patients with diagnosis of ET rarely determines the decision to initiate cytoreductive therapies. In our study, we compared different risk models to estimate the thrombotic risk of 233 ET patients and the role of …

Thrombotic riskmedicine.medical_specialtyArticle SubjectEssential thrombocythemiabusiness.industryCardiovascular risk factorsMEDLINEHematologymedicine.diseaseThrombosisObesitySettore MED/15 - Malattie Del Sangue03 medical and health sciencesVenous thrombosis0302 clinical medicine030220 oncology & carcinogenesisDiabetes mellitusmedicineDiseases of the blood and blood-forming organsRC633-647.5Intensive care medicinebusinesspolycythemia vera essential thrombocytemia030215 immunologyResearch ArticleAdvances in Hematology
researchProduct

Transdermal Nitroglycerine Patch: An Optional Device to Reduce Flap Venous Congestion? A Case Report

2013

ABSTRACT Sometimes in free flap there is a venous congestion without an obstruction of the venous anastomosis or other organic causes of reduction venous drainage (haematoma, seroma compressing the pedicle). In these cases the authors suggest the application of nitroglycerine patch in the congested area of the flap few hours before the surgical exploration of the anastomosis. If there is a fast improvement of the clinical feature of the flap, the surgical exploration could be avoided. The authors underline that applying the nitroglycerin patch should not be regarded in any way as a therapy of a free flap venous thrombosis but only as an useful device, an option to be taken only when the sur…

Venous Congestionmedicine.medical_specialtybusiness.industryVascular Pedicle Thrombosimedicine.medical_treatmentSettore MED/19 - Chirurgia PlasticaFree flapMicrosurgical ComplicationsAnastomosismedicine.diseaseSurgeryVenous thrombosisVenous congestionAnesthesiaSeromamedicineVenous anastomosisbusinessFree Flap FailureReduction (orthopedic surgery)Transdermal
researchProduct

Superior mesenteric vein thrombosis following open right hemicolectomy and cholecystectomy. Case report

2020

INTRODUZIONE: La SMVT è una seria, rara complicanza della chirurgia addominale. I fattori di rischio sono molteplici, ma scarsamente descritti tanto che i dati sono insufficienti per creare gold standard per la diagnosi e trattamento. La SMVT ha un ampio spettro di presentazioni cliniche, così che spesso la sua diagnosi precoce può essere complessa. CASE REPORT: Una donna obesa di 56 anni con un disordine protrombotico ereditario è stata sottoposta ad emicolectomia destra e colecistectomia open; l’immediato decorso post-operatorio è stato regolare e la paziente è stata dimessa in quinta giornata post-operatoria. In ottava giornata post-operatoria la paziente ha presentato dolore addominale …

Venous ThrombosisMesenteric VeinsPostoperative ComplicationsColorectal surgery Superior mesenteric vein thrombosis Hypercoagulable disorders ThromboprophylaxisHumansthrombosiCholecystectomyFemaleMiddle Agedcholecystectomy.right hemicolectomyColectomySuperior mesenteric vein
researchProduct

Thrombotic complications of vaccination against SARS-CoV-2: what pharmacovigilance reports tell us – and what they don't

2021

In the present issue of the Journal [1], Smadja et al. present an analysis of global pharmacovigilance reports of thrombotic events following severe acute respiratory distress syndrome coronavirus (SARS-CoV)-2 vaccination. More specifically, the authors analysed the data entered into the World Health Organization (WHO) Global Database for Individual Case Safety Reports (VigiBase) between December 13, 2020 and March 16, 2021, covering, at that time, a population of almost 362 million vaccinated individuals across the world. The study focuses on three of the coronavirus disease (COVID)-19 vaccines available to date, namely the Pfizer-BioNtech (BNT162b2), Moderna (mRNA-1273), and OxfordAstraZe…

Venous ThrombosisPulmonary and Respiratory Medicine2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)SARS-CoV-2business.industrySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VaccinationCOVID-19ThrombosisVaccination03 medical and health sciencesEditorial0302 clinical medicine030228 respiratory systemPharmacovigilancemedicineHumans030212 general & internal medicineIntensive care medicinebusinessThrombotic complicationEuropean Respiratory Journal
researchProduct

Activación plaquetaria e hipercolesterolemia en la patogenia de la trombosis venosa profunda

2006

Currently it is accepted that deep vein thrombosis is a multifactorial event in which the presence of activated platelets and also plasmatic lipids seems to play a pivotal role that it is not well established in the scientific bibliography. Due to the non consensus state about these topics between the different groups working in these aspects, the topic involving deep vein thrombosis-platelets-lipids, and also their interactions, still is an interesting area of investigation, in which it is necessary to carry out studies with the aim of establishing risk factors, initial diagnostic methods and clinical assays to probe the efficacy of new therapies.

Venous thrombosisDiagnostic methodsmedicine.anatomical_structurebusiness.industryDeep veinmedicineGeneral MedicinePlatelet activationmedicine.diseaseBioinformaticsbusinessThrombosisMedicina Clínica
researchProduct

2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism

2014

ACS : acute coronary syndrome AMPLIFY : Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-line Therapy aPTT : activated partial thromboplastin time b.i.d. : bis in diem (twice daily) b.p.m. : beats per minute BNP : brain natriuretic peptide BP : blood pressure CI : confidence interval CO : cardiac output COPD : chronic obstructive pulmonary disease CPG : Committee for Practice Guidelines CRNM : clinically relevant non-major CT : computed tomographic/tomogram CTEPH : chronic thromboembolic pulmonary hypertension CUS : compression venous ultrasonography DSA : digital subtraction angiography DVT : deep vein thrombosis ELISA : enzyme-linked immunosorben…

Vitamin KVasodilator AgentsAdministration OralChest pain; Diagnosis; Dyspnoea; Guidelines; Heart failure; Hypotension; Pulmonary embolism; Shock; Thrombolysis; Treatment-Anticoagulation; Venousthrombosis; Administration Oral; Algorithms; Anticoagulants; Biomarkers; Chronic Disease; Clinical Laboratory Techniques; Diagnostic Imaging; Embolectomy; Endovascular Procedures; Female; Fibrin Fibrinogen Degradation Products; Fibrinolytic Agents; Heart Failure; Home Care Services; Humans; Hypertension Pulmonary; Long-Term Care; Neoplasms; Pregnancy; Pregnancy Complications Cardiovascular; Prognosis; Pulmonary Embolism; Risk Factors; Vasoconstrictor Agents; Vasodilator Agents; Vitamin K; Cardiology and Cardiovascular MedicineEmbolectomyCardiovascularChest painPregnancyRisk FactorsNeoplasmsDiagnosisVasoconstrictor AgentsSocieties MedicalEndovascular ProceduresShockGeneral MedicinePulmonaryPrognosisThrombosisThrombolysisHome Care ServicesPulmonary embolismEuropeVenous thrombosismedicine.veinPractice Guidelines as TopicAdministrationHypertensionCardiologyApixabanFemaleRadiologyHypotensionCardiology and Cardiovascular MedicineAlgorithmsmedicine.drugOralDiagnostic Imagingmedicine.medical_specialtypumonary hypertensionmedicine.drug_classHypertension PulmonaryPregnancy Complications CardiovascularCardiologyMEDLINELow molecular weight heparin610 Medicine & healthHeart failureGuidelinesInferior vena cavaFibrin Fibrinogen Degradation ProductsText miningFibrinolytic AgentsInternal medicineDyspnoeamedicineHumansIntensive care medicinebusiness.industryClinical Laboratory TechniquesPulmonary embolismAnticoagulantsTreatment-Anticoagulationmedicine.diseasePulmonary hypertensionLong-Term CarePregnancy ComplicationsVenousthrombosisHeart failureChronic DiseasebusinessBiomarkers
researchProduct

Aspirin for preventing the recurrence of venous thromboembolism

2012

aspirin venous thrombosis
researchProduct

Prognostic relevance of an asymptomatic venous thromboembolism in patients with cance

2011

cancer and venous thrombosisSettore MED/15 - Malattie Del Sangue
researchProduct

Endovascular treatment for chronic cerebrospinal venous insufficiency: is the procedure safe?

2010

Objectives The aim of this report is to assess the safety of endovascular treatment for chronic cerebrospinal venous insufficiency (CCSVI). Although balloon angioplasty and stenting seem to be safe procedures, there are currently no data on the treatment of a large group of patients with this vascular pathology. Methods A total of 564 endovascular procedures (balloon angioplasty or, if this procedure failed, stenting) were performed during 344 interventions in 331 CCSVI patients with associated multiple sclerosis. Results Balloon angioplasty alone was performed in 192 cases (55.8%), whereas the stenting of at least one vein was required in the remaining 152 cases (44.2%). There were no majo…

endovascular treatmentAdultMalemedicine.medical_specialtyMultiple SclerosisAdolescentmedicine.medical_treatmentFemoral veinBalloonYoung AdultPostoperative ComplicationsCentral Nervous System DiseasesAngioplastymedicineHumansVeinAgedbusiness.industryEndovascular ProceduresStentPhlebographyGeneral MedicineMiddle Agedmedicine.diseaseSurgeryVenous thrombosisChronic cerebrospinal venous insufficiencymedicine.anatomical_structureVenous InsufficiencyChronic DiseaseFemaleStentsRadiologyCardiology and Cardiovascular MedicineVenous malformationbusinessvenous malformationAngioplasty BalloonMagnetic Resonance AngiographyPhlebology: The Journal of Venous Disease
researchProduct

Complement C5 but not C3 is expendable for tissue factor activation by cofactor-independent antiphospholipid antibodies

2018

The complement and coagulation cascades interact at multiple levels in thrombosis and inflammatory diseases. In venous thrombosis, complement factor 3 (C3) is crucial for platelet and tissue factor (TF) procoagulant activation dependent on protein disulfide isomerase (PDI). Furthermore, C5 selectively contributes to the exposure of leukocyte procoagulant phosphatidylserine (PS), which is a prerequisite for rapid activation of monocyte TF and fibrin formation in thrombosis. Here, we show that monoclonal cofactor-independent antiphospholipid antibodies (aPLs) rapidly activate TF on myelomonocytic cells. TF activation is blocked by PDI inhibitor and an anti-TF antibody interfering with PDI bin…

inorganic chemicals0301 basic medicineComplement factor I030204 cardiovascular system & hematologyMonocytesImmunoglobulin GThromboplastinThrombosis and HemostasisMice03 medical and health sciencesTissue factor0302 clinical medicineimmune system diseasesmedicineAnimalsPlateletneoplasmsBlood CoagulationMice KnockoutVenous ThrombosisComplement component 5biologyChemistryMonocyteComplement C5Complement C3Hematologynervous system diseasesbody regions030104 developmental biologymedicine.anatomical_structureCoagulationAntibodies Antiphospholipidbiology.proteinCancer researchAntibodyBlood Advances
researchProduct